scispace - formally typeset
E

Erin Murphy

Researcher at Merck & Co.

Publications -  49
Citations -  17499

Erin Murphy is an academic researcher from Merck & Co.. The author has contributed to research in topics: Pembrolizumab & Immunotherapy. The author has an hindex of 30, co-authored 49 publications receiving 15077 citations. Previous affiliations of Erin Murphy include Schering-Plough.

Papers
More filters
Journal ArticleDOI

Involvement of chemokine receptors in breast cancer metastasis.

TL;DR: It is reported that the chemokine receptors CXCR4 and CCR7 are highly expressed in human breast cancer cells, malignant breast tumours and metastases and their respective ligands CXCL12/SDF-1α and CCL21/6Ckine exhibit peak levels of expression in organs representing the first destinations of breast cancer metastasis.
Journal ArticleDOI

IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines

TL;DR: A member of theIL-1 family, IL-33, which mediates its biological effects via IL-1 receptor ST 2, activates NF-kappaB and MAP kinases, and drives production of T(H)2-associated cytokines from in vitro polarized T( H)2 cells is reported.
Journal ArticleDOI

IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade

TL;DR: The T cell–inflamed GEP contained IFN-&ggr;–responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit.
Journal ArticleDOI

IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis.

TL;DR: Indirect intradermal administration of IL-23 in mouse skin initiates a tumor necrosis factor–dependent, but IL-17A–independent, cascade of events resulting in erythema, mixed dermal infiltrate, and epidermal hyperplasia associated with parakeratosis.